Vijaya Diagnostic Centre Ltd Q1 FY27 Results Analysis: PAT Surges 38%, EBITDA Margin Above Guidance
Cofacto Research
Updated August 07, 2026
2 min read
Positive
Vijaya Diagnostic Centre Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 230.98 Cr (+22.83% YoY) and PAT growth of +37.61% YoY. Here's a quick read of what worked, what to watch, and what management said.
Quick Details| Results date | August 06, 2026 |
|---|
| Quarter | Q1 FY 2026-2027 |
|---|
| Revenue (Q1) | Rs. 230.98 Cr (+22.83% YoY) |
|---|
| PAT (Q1) | Rs. 53.10 Cr (+37.61% YoY) |
|---|
| EBITDA margin | 42.66% (+356 bps YoY) |
|---|
| EPS (Q1) | Rs. 5.16 (+37.23% YoY) |
|---|
| Market cap | Rs. 14,108.63 Cr |
|---|
| CMP | Rs. 1,369.80 |
|---|
Quarter Snapshot
VIJAYA delivered a strong Q1 with revenue growing 22.83% YoY and EBITDA margin of 42.66%, comfortably above the ~40% guidance floor. PAT surged 37.61% YoY on operating leverage as expenses improved 301 bps as a percentage of revenue. Network expansion drove asset growth, though finance costs and leverage increased as expected during the investment phase.
Key Investment Insights
Key Positives
- Revenue grew 22.83% YoY to Rs.230.98 Cr, with sequential growth of 5.29% despite seasonal Q1 weakness
- EBITDA margin of 42.66% came in above the ~40% management guidance floor, expanding 356 bps YoY
- PAT grew 37.61% YoY to Rs.53.10 Cr, outpacing revenue growth due to operating leverage
- Total expenses as % of revenue improved from 75.99% to 72.98% YoY, a 301 bps reduction
- Net worth increased 5.7% QoQ to Rs.1,012.03 Cr from retained profits
Risk Factors
- Finance costs grew 47% YoY (Rs.11.00 Cr vs Rs.7.49 Cr) and 18% QoQ, driven by lease liabilities and working capital borrowings
- Debt-to-equity ratio increased from 57.45% to 65.70% QoQ as liabilities grew faster than assets
- Subsidiaries (new hubs) contributed Rs.12.44 Cr in revenue but a marginal PAT loss of Rs.0.05 Cr
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.
Powered by Cofacto — AI research platform for Indian stocks, every claim cited from primary filings
Login Now